Veltassa
Drug - Veltassa™ (patiromer) [Relypsa, Inc.]
March 2016
Therapeutic area - Hyperkalemia
Approval criteria
- Patient has a diagnosis of chronic hyperkalemia AND one of the following:
- Patient has tried and failed sodium polystyrene sulfonate OR
- Patient has a known hypersensitivity to sodium polystyrene sulfonate
Quantity limit
- Maximum of one packet daily (34 packets per 34 days)
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411
